What ChondroFiller does in a hip cartilage defect

Focal cartilage damage in the hip — a patch of worn or missing tissue on the acetabular surface — does not heal well on its own. ChondroFiller® (also marketed as Liquid Cartilage™) is a CE-marked Class III medical device designed to give that repair process somewhere to start.

The treatment is an injectable collagen scaffold, not a drug or a surgical implant. When placed into a cartilage defect under ultrasound guidance, the liquid rapidly gels in situ, forming a porous, three-dimensional matrix. That matrix acts as a scaffold the body can work with: progenitor cells migrate from the surrounding synovium and subchondral bone into the collagen structure, where they differentiate and begin producing new tissue. This process is termed acellular matrix-induced chondrogenesis — the scaffold itself contains no cells, but it is chemotactic, drawing the patient's own cells in to support the body's natural repair processes. In an ex vivo osteochondral model, ChondroFiller-treated defects showed a 2.4-fold increase in DNA content by day 14, confirming that active cell recruitment does occur.

For the hip specifically, the published clinical experience centres on focal acetabular lesions greater than 2 cm² — the size range where conservative measures typically offer little and open surgery feels disproportionate. ChondroFiller is not a treatment for widespread joint degeneration; background osteoarthritis significantly worsens outcomes, so patient selection matters.

In current clinical practice, ChondroFiller is delivered as an outpatient, ultrasound-guided injection — no theatre admission, no incisions, no general anaesthetic. That procedural context shapes nearly everything about how the treatment is planned and performed in the hip.

Why the hip joint makes needle placement harder than the knee

The knee sits just beneath the skin, surrounded by relatively thin soft tissue — an experienced clinician can often feel the joint line clearly and estimate the needle's position with reasonable confidence. The hip is built very differently, and that difference is what makes image guidance essential rather than merely preferable.

Sitting deep inside the pelvis, the hip is a ball-and-socket joint wrapped in some of the largest and thickest muscle groups in the body. Reaching the joint cavity typically requires a needle to travel 8–12 cm through layers of gluteal muscle and adipose tissue before it arrives at the joint space. Over that distance, the subtle tactile cues a clinician would ordinarily rely on — the slight give as a needle crosses a tissue boundary, resistance changes as it approaches bone — become far harder to interpret. Small deviations in angle or depth that would be inconsequential near the surface translate into significant positional errors by the time the tip reaches its target.

Surface landmarks are also less informative here. The bony reference points used to estimate needle position — the greater trochanter and anterior superior iliac spine — sit some distance from the actual joint, and body composition varies considerably between patients. What works as a reliable estimate in one person may miss by a centimetre or more in another.

Adding to this complexity, the femoral nerve, artery, and vein run close to the anterior approach to the hip joint. An imprecise needle path carries a greater margin for error than in a more superficial joint — which is why the clinical literature on hip injection technique is built around imaging guidance as standard, not as an optional refinement.

The accuracy gap between ultrasound-guided and landmark-guided hip injection

Up to 30% of landmark-guided intra-articular injections may miss the intended target site — roughly one in three 'blind' placements landing in periarticular tissue rather than within the joint cavity. That figure, drawn from orthobiologic injection practice, reflects how unreliable surface estimation alone can be when the target is small, deep, and invisible.

Direct comparison data quantify what ultrasound changes: image-guided intra-articular injections achieve approximately 89% placement accuracy versus around 58% for landmark-guided technique — a 31-percentage-point difference. Operator experience compounds the gap further; the advantage of guided over unguided placement is widest among less experienced practitioners, making imaging support especially valuable in settings where hip injection is not a high-frequency procedure.

These figures come from general intra-articular injection research; no ChondroFiller-specific accuracy study in the human hip exists yet. Even so, the principle applies with particular force here. The hip demands an 8–12 cm needle path through substantial muscle and adipose tissue — the same anatomical conditions that make landmark estimation unreliable in the first place. For a collagen scaffold that must gel within a focal defect to recruit cells effectively, an inaccurate placement into periarticular soft tissue renders the treatment non-functional. The 31-point accuracy advantage of ultrasound guidance is, in that context, a clinical rationale rather than a procedural preference.

Why dosing precision and placement affect how the scaffold performs

Knowing the needle has reached the joint space is only part of the challenge — what matters next is where within that space the gel is deposited, and how much is delivered.

ChondroFiller has an important biomechanical characteristic: when it first gels, the collagen matrix is mechanically unstable under load. It needs time to mature within the defect before it can withstand the forces of normal joint movement. If the gel is placed outside the lesion — into the synovial recess or periarticular tissue rather than into the cartilage defect itself — it is removed from the biological environment it needs: subchondral bone below and cartilage margins around it, both of which provide the progenitor cells the scaffold is designed to recruit. In that situation, the material may simply be resorbed without contributing to repair.

Volume precision matters separately. Data from wrist-application studies — where ChondroFiller was used to treat focal intra-articular cartilage lesions — found that overfilling a defect led to fibrous rather than cartilaginous tissue formation, while flush, precisely dosed applications (typically 0.2–0.3 mL of the 1 mL preparation) were free of this complication. This dose-sensitivity signal has not been studied specifically in the hip, but the underlying principle — that the scaffold must fill a defect accurately, not overflow it — is a property of the material itself.

Real-time ultrasound guidance addresses both concerns simultaneously. The clinician can confirm needle-tip position before releasing any volume, then observe filling as it happens, stopping at the point where the defect is flush. Placement accuracy is therefore not only a safety measure but a direct determinant of whether the scaffold can perform as intended.

Which patients are usually assessed for ChondroFiller hip injection

The best available evidence for ChondroFiller in the hip comes from a prospective cohort of 26 patients with femoroacetabular impingement and acetabular cartilage lesions larger than 2 cm². Among the 21 patients evaluable at 3–5 year follow-up, 17 reported good or excellent outcomes — a result that holds across multiple years of observation, not just early post-procedure recovery. The Modified Harris Hip Score improved by approximately 30 points in patients who met appropriate selection criteria, and this figure serves as the primary outcome anchor for hip-specific treatment discussions.

The single most important eligibility filter is the absence of advanced background osteoarthritis. Patients with Tönnis grade 2–3 changes had poor results in this cohort; the scaffold is designed to support repair within a focal defect, and that mechanism is undermined when the surrounding cartilage and subchondral bone are already substantially degraded. This is not a reason to dismiss ChondroFiller outright, but it does mean that staging the disease accurately before any treatment decision matters considerably.

Confirming a focal rather than generalised pattern of damage requires imaging — typically MRI to characterise the lesion and plain X-ray for OA grading — as part of the specialist assessment.

These outcome figures derive from an arthroscopic delivery cohort, which is the strongest clinical evidence currently available. They are the best reference point for ultrasound-guided injection, but they are not a direct guarantee of what injection-route delivery will produce; no injection-specific hip study yet exists.

Finding a specialist who offers ChondroFiller hip injection

Bringing the clinical picture together: the patient most likely to benefit is one with a focal acetabular defect, limited background osteoarthritis, and a lesion confirmed on imaging — the profile the existing cohort evidence supports. The practical challenge from that point is finding a practitioner who combines expertise in ChondroFiller / Liquid Cartilage with competence in ultrasound-guided hip injection technique, since those skills do not always sit in the same clinic.

At consultation, two questions carry real clinical weight. First, ask whether the specialist uses real-time ultrasound guidance specifically for hip injections — not just for knee or shoulder work. Second, ask how they confirm needle-tip position before releasing the gel, and how they manage dosing within the defect. These are not bureaucratic questions; placement accuracy and volume control directly affect whether the collagen scaffold can perform as intended, as the delivery environment and biomechanical considerations set out above make clear.

Search MSK lists specialists across the UK who offer ChondroFiller / Liquid Cartilage injection — use the region and specialty filters to identify a practitioner whose assessment pathway matches the criteria described here.